Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Semaglutide, the active ingredient in diabetes medications Ozempic and Wegovy, was associated with a significantly reduced ...

R esearch shows that GLP-1 receptor agonists like Ozempic can help you drop weight, manage diabetes, and even potentially lower the risk of opioid overdoses. But now, a new study finds that taking ...

Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also ...

A blockbuster diabetes and weight-loss drug might be doing more than controlling blood sugar—it could also be protecting the ...

Amanda Bynes Ozempic weight loss journey is making headlines as the former Nickelodeon star revealed plans to lose over 40 ...

A massive U.S. study found diabetics on semaglutide (Ozempic’s active ingredient) had up to 70% lower risk of ...

Diabetes drug semaglutide linked to reduced risk of dementia in type 2 diabetes patients Effects strongest in women and older ...

Research out today is the latest to suggest that semaglutide can significantly lower people's risk of dementia.

Obesity and diabetes drugs, particularly semaglutides like Wegovy and Ozempic, may reduce a person’s risk of dementia, a new study suggests. Researchers found these medications show promise in ...

An analysis of 1.7 million patients shows semaglutide may significantly reduce Alzheimer and vascular dementia risk compared with other diabetes drugs.

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.